TY - JOUR
T1 - OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer
AU - Tammela, Jonathan
AU - Uenaka, Akiko
AU - Ono, Toshiro
AU - Noguchi, Yuji
AU - Jungbluth, Achim A.
AU - Mhawech-Fauceglia, Paulette
AU - Qian, Feng
AU - Schneider, Sally
AU - Sharma, Sameer
AU - Driscoll, Deborah
AU - Lele, Shashikant
AU - Old, Lloyd J.
AU - Nakayama, Eiichi
AU - Odunsi, Kunle
PY - 2006/10
Y1 - 2006/10
N2 - OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69% of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.
AB - OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients were tested for OY-TES-1 antibody by ELISA. Thymus and leukocytes were weakly positive for OY-TES-1 while the remaining 5 normal tissues were negative. Expression of OY-TES-1 by either RT-PCR and/or IHC was demonstrable in 69/100 (69%) tumors. Humoral immunity to OY-TES-1 was demonstrated in 1/10 (10%) serum samples from patients whose tumors expressed the antigen. The median follow-up of the patient population was 34 months. There was no correlation between antigen expression and stage, grade, histology and survival. OY-TES-1 is expressed in 69% of patients with EOC, is absent from normal ovarian tissue, and a proportion of patients show evidence of a specific humoral immune response. These findings make OY-TES-1 an attractive target for antigen-specific immunotherapy in EOC.
KW - Antibody
KW - Immunogenicity
KW - Immunohistochemistry
KW - Ovarian tumor antigen
KW - Prognostic indicator
UR - http://www.scopus.com/inward/record.url?scp=38949172355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38949172355&partnerID=8YFLogxK
U2 - 10.3892/ijo.29.4.903
DO - 10.3892/ijo.29.4.903
M3 - Article
C2 - 16964386
AN - SCOPUS:38949172355
SN - 1019-6439
VL - 29
SP - 903
EP - 910
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 4
ER -
